IP Library Granted Patent US 8,859,623
Granted Patent B1
US 8,859,623 · App. 14/080,771 · Granted Oct 14, 2014

Methods and compositions of stable phenylephrine formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,623
App. No.
14/080,771
Granted
Oct 14, 2014
Kind
B1
Abstract

The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months.

Claims (14)

1. A method of using an ophthalmic composition for pupil dilation, the composition comprising R-phenylephrine hydrochloride having an initial chiral purity of at least 95% and an aqueous buffer, wherein the chiral purity of R-phenylephrine hydrochloride is at least 95% of the initial chiral purity after 6 months, the method comprising:

administering the composition into an eye of an individual in need thereof, wherein the composition is stored between −10 to 10 degree Celsius prior to administration, and wherein the composition comprises R-phenylephrine hydrochloride having a chiral purity of at least 95% when administered after storage.

2. The method of claim 1 , wherein the composition is allowed to be stored between 2 to 8 degree Celsius.

3. The method of claim 1 , wherein the composition comprises R-phenylephrine hydrochloride having an initial chiral purity of at least 99%.

4. The method of claim 1 , wherein the composition comprises R-phenylephrine hydrochloride having an initial chiral purity of at least 99.3%.

5. The method of claim 1 , wherein the chiral purity of R-phenylephrine hydrochloride is at least 97% of the initial chiral purity after 6 months.

6. The method of claim 1 , wherein the chiral purity of R-phenylephrine hydrochloride is at least 99% of the initial chiral purity after 6 months.

7. The method of claim 1 , wherein the chiral purity of R-phenylephrine hydrochloride is at least 99.5% of the initial chiral purity after 6 months.

8. The method of claim 1 , wherein the composition comprises 2.5% w/v or 10% w/v R-phenylephrine hydrochloride by weight.

9. The method of claim 1 , wherein the composition is packaged in a 1-15 ml plastic or glass bottle.

10. The method of claim 9 , wherein the package identifies storing the composition at a temperature between −10 to 10 C.

11. The method of claim 10 , wherein the package identifies storing the composition at a temperature between 2 to 8 C.

12. The method of claim 9 , wherein the composition is in a plastic or glass bottle of about 2 ml, about 3 ml, about 5 ml, about 10 ml or about 15 ml.

13. The method of claim 9 , wherein the plastic or glass bottle is opaque.

Assignments (5)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (067501/0955) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0665 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 23, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 067527/0251 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 22, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 067501/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2013
From: WITHAM, PATRICK H; MACHIRAJU, SAILAJA; BLUETT, LAUREN MACKENSIE-CLARK
To: PARAGON BIOTECK, INC.
Reel/Frame 031813/0424 →